Actions of IGFBP on Epithelial Cancer Cells: Potential for New Therapeutic Targets

IGF-Binding Protein - Cancer Cells - Therapy

References

• 1 Folkman J, Hahnfeld P, Hlatky L. Cancer: looking outside the genome.  Nat Rev Mol Cell Biol. 2000;  1 76-79
• 2 Li F P. Identification and management of inherited cancer susceptibility.  Environ Health Perspect. 1995;  103 Suppl 8 297-300
• 3 Lichtenstein P, Holm N V, Verkasalo P K. et al . Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland.  N Engl J Med. 2000;  343 78-85
• 4 LeRoith D, Roberts C T Jr. The Insulin-like growth factor system and cancer.  Cancer Lett. 2003;  195 (2) 127-137
• 5 Chan J M, Stampfer M J, Giovannucci E. et al . Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.  Science. 1998;  279 563-566
• 6 Hankinson S E, Willett W C, Colditz G A. et al . Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.  Lancet. 1998;  351 1393-1396
• 7 Ma J, Pollak M N, Giovannucci E. et al . Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.  J Natl Cancer Inst. 1999;  91 620-625
• 8 Giovannucci E, Pollak M N, Platz E A. et al . A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women.  Cancer Epidemiol Biomarkers Prev. 2000;  9 345-349
• 9 Shi R, Berkel H J, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis.  Br J Cancer. 2001;  85 991-996
• 10 Pollak M, Blouin M J, Zhang J C, Kopchick J J. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist.  Br J Cancer. 2001;  85 428-430
• 11 Yakar S, Wu Y, Zhao L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis.  Cancer Res 2002. 15;  62 (4) 1030-1035
• 12 Wuy . et al . Cancer and Insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk.  BMJ. 2000;  321 847-848
• 13 Lagopoulos L, Sunahara G I, Wurzner H, Dombrowsky I, Stalder R. The effects of alternating dietary restriction and ad libitum feeding of mice on the development of diethylnitrosamine-induced liver tumours and its correlation to insulinaemia.  Carcinogenesis. 1991;  12 311-315
• 14 Hursting S D, Switzer B R, French J E, Kari F W. The growth hormone: insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats.  Cancer Res. 1993;  53 2750-2757
• 15 Mukherjee P, Sotnikov A V, Mangian H J, Zhou J R, Visek W J, Clinton S K. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression.  J Natl Cancer Inst. 1999;  91 512-523
• 16 Dunn S E, Kari F W, French J. et al . Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice.  Cancer Res. 1997;  57 4667-4672
• 17 Rohlik Q T, Adams D, Kull F C Jr, Jacobs S. An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture.  Biochem Biophys Res Commun. 1987;  149 276-281
• 18 Ludwig D, Burtrom D, Lu D. et al . A fully human monoclonal antibody to the human IGF-1 receptor that blocks ligand-dependent signaling and inhibits the growth of multiple human tumors in nude mice.  AACR, Washington DC. 2003;  Abstract 761 174
• 19 Sachdev D, Li S L, Hartell J S, Fujita-Yamaguchi Y, Miller J S, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-1.  Cancer Res. 2003;  63 627-35
• 20 Hellawell G O, Ferguson D J, Brewster S F, Macaulay V M. Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor.  BJU Int. 2003;  91 271-277
• 21 Blum G, Gazit A, Levitzki A. Development of new IGF-1 receptor kinase inhibitors using catechol mimics.  J Biol Chem. 2003;  278 (42) 40442-40454
• 22 Hofmann F, Brueggen J, Pearson M. In vitro and in vivo profiling of selective and potent IGF-1R kinase inhibitors.  AACR, Washington DC. 2003;  Abstract 3798 756
• 23 Firth S M, Baxter R C. Cellular Actions of the Insulin-Like Growth Factor Binding Proteins.  Endocrine Review. 2002;  23 (6) 824-854
• 24 Conover C A. Glycosylation of insulin-like growth factor binding protein-3 (IGFBP-3) is not required for potentiation of IGF-1 action: evidence for processing of cell-bound IGFBP-3.  Endocrinology. 1991;  129 (6) 3259-3268
• 25 Jones J I. et al . Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-1.  J Cell Biol. 1993;  121 (3) 679-687
• 26 Oh Y, Muller H L, Ng L, Rosenfeld R G. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action.  J Biol Chem. 1995;  270 13 589-13 592
• 27 Gucev Z S, Oh Y, Kelly K M, Rosenfeld R G. Insulin-like growth factor binding protein 3 mediates retinoic acid and transforming growth factor beta-2 induced growth inhibition human breast cancer cells.  Cancer Res. 1996;  56 (7) 1545-1550
• 28 Colston K W, Perks C M, Xie S P, Holly J M. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3.  J Mol Endocrinol. 1998;  20 157-162
• 29 Rozen F, Zhang J, Pollak M. Antiproliferative action of tumour necrosis factor-alpha on MCF-7 breast cancer cells is associated with increased insulin-like growth factor-binding protein-3 accumulation.  Int J Oncol. 1998;  13 865-869
• 30 Nishimura A, Fujimoto M, Oguchi S, Fusunyan R D, MacDermott R P, Sanderson I R. Short-chain fatty acids regulate IGF-binding protein secretion by intestinal epithelial cells.  Am J Physiol. 1998;  275 E55-E63
• 31 Huynh H, Yang X F, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor-binding protein-3 autocrine loop in human breast cancer cells.  J Biol Chem. 1996;  271 1016-1021
• 32 Zi X, Zhang J, Agarwal R, Pollak M. Silibinin ip-regulates insulin-like growth factor-binding protein 3 ecxpression and inhibits proliferation of androgen-independent prostate cancer cells.  Cancer Res. 2000;  60 (20) 5617-5620
• 33 Buckbinder L, Talbott R, Velasco-Miguel R, Takenaka I, Faha B, Seizinger B R, Ley N. Induction of the growth inhibitor IGF-binding protein 3 by p53.  Nature. 1995;  377 646-649
• 34 Tonner E, Barber M C, Travers M T, Logan A, Flint D J. Hormonal control of insulin-like growth factor binding protein-5 production in the involuting mammary gland of the rat.  Endocrinology. 1997;  138 5101-5107
• 35 Thomas L N, Wright A S, Lazier C B, Cohen P, Rittmaster R S. Prostatic involution on men taking finasteride is associated with elevated levels in insulin-like growth factor-binding proteins (IGFBPS-2, -4 and -5).  Prostate 2000 Feb 15. 42 (3) 203-210
• 36 Phillips I D, Becks G P, Logan A, Wang J F, Smith C, Hill D J. Altered expression of insulin-like growth factor I (IGF-1) and IGI binding proteins during rat thyroid hyperplasia and involution.  Growth Factors. 1994;  10 (3) 207-222
• 37 Liu X J, Malkowski M, Guo Y, Erickson G F, Shimasaki S, Ling N. Development of specific antibodies to rat insulin-like growth factors binding proteins (IGFBP-2 to -6): analysis of IGFBP production in rat granulosa cells.  Endocrinology. 1993;  132 (3) 1176-1183
• 38 Jones J I, Clemmons D R. Insulin-like growth factors and their binding proteins: biological actions.  Endocr Rev. 1995;  16 (1) 3-34
• 39 Blum W F. et al . Insulin-like growth factor I (IGF-1) binding protein complex is a better mitogen than free IGF-1.  Endocrinology. 1989;  125 (2) 766-772
• 40 Ritvos O. et al . Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-1 in cultured choriocarcinoma cells.  Endocrinology. 1988;  122 (5) 2150-2157
• 41 Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells.  Biochem Biophys Res Commun. 1997;  237 (3) 690-693
• 42 Conover C A, Powell D R. Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-1 induced receptor down-regulation and cell desensitisation in cultured bovine fibroblasts.  Endocrinology. 1991;  129 710-716
• 43 Conover C A. Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism.  Endocrinology. 1992;  130 3191-3199
• 44 Conover C A, Bale L K, Durham S K, Powell D R. Insulin-like growth factor (IGF) binding protein-3 potentiation of IGF action is mediated through the phosphatidylinositol-3-kinase pathway and is associated with alteration in protein kinase B/AKT sensitivity.  Endocrinology. 2000;  141 3098-3103
• 45 Cohen P, Peehl D M, Graves H C, Rosenfeld R G. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease.  J Endocrinology. 1994;  142 407-415
• 46 Lalou C, Lassarre C, Binoux M. Isolation and characterisation of proteolytic fragments of insulin-like growth factor-binding protein-3.  Horm Res. 1996;  45 156-159
• 47 Angelloz-Nicoud P, Lalou C, Binoux M. Prostate carcinoma (PC-3) cell proliferation is stimulated by the 22 - 25-kDa proteolytic fragment (1 - 60) and inhibited by the 16-kDa fragment (1 - 95) if recombinant human insulin-like factor binding protein-3.  Growth Horm IGF Res. 1998;  8 71-75
• 48 Nam T J. et al . Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-1-stimulated cell growth.  Endocrinology. 2000;  141 (3) 1100-1106
• 49 Clemmons D R, Maile L A. Integral membrane proteins that function co-ordinate with the insulin-like growth factor I receptor to regulate intracellular signalling.  Endocrinology. 2003;  144 (5) 1664-1670
• 50 Liu L, Delbe J, Blat C, Zapf J, Harel L. Insulin-like growth factor binding protein (IGFBP-3) an inhibition of serums growth factors other than IGF-1 and-II. J.  Cell Physiol. 1992;  153 (1) 15-21
• 51 Oh Y, Muller H L, Lamson G, Rosenfeld R G. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition.  J Biol Chem. 1993;  268 (20) 14 964-14 971
• 52 McCaig C. et al . Differential interactions between IGFBP-3 and transforming growth factor-beta (TGFβ) in normal vs. cancerous breast epithelial cells.  Br J Cancer. 2002;  86 (12) 1963-1969
• 53 Butt A J. et al . Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells.  J Biol Chem. 2000;  275 (50) 39 174-39 181
• 54 Rajah R, Valentinis B, Cohen P. Insulin Like growth factor (IGF) binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53- and IGF-1-independent mechanism.  J Biol Chem. 1999;  272 (18) 1281-1288
• 55 Gill Z P. et al . Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner.  J Biol Chem. 1997;  272 (41) 25 602-25 607
• 56 Fowler C A. et al . Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells.  Int J Cancer. 2000;  88 (3) 448-453
• 57 Perks C M, McCaig C, Holly J M. Differential insulin-like growth factor (IGF)-independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria.  J Cell Biochem. 2000;  80 (2) 248-258
• 58 Williams A C. et al . Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells.  Cancer Res. 2000;  60 (1) 22-27
• 59 Hollowood A D. et al . IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation.  Int J Cancer. 2000;  88 (3) 336-341
• 60 Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-1-independent mechanism.  J Biol Chem. 1997;  272 (18) 12 181-12 188
• 61 Perks C M. et al . Differential IGF-1-independent effects of insulin-like growth factor binding proteins (1 - 6) on apoptosis of breast epithelial cells.  J Cell Biochem. 1999;  75 (4) 652-664
• 62 Norgaard P. et al . Transforming growth factor beta and cancer.  Cancer Treat Rev. 1995;  21 (4) 367-403
• 63 McCaig C, Perks C M, Holly J M. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin.  J Cell Sci. 2002;  115 (Pt 22) 4293-303
• 64 Yamada K M, Clark K. Cell biology: survival in three dimensions.  Nature. 2002;  419 (6909) 790-791
• 65 Perks C M. et al . Effects of a non-IGF binding mutant of IGFBP-5 on cell death in human breast cancer cells.  Biochem Biophys Res Commun. 2002;  294 (5) 995-1000
• 66 Lalou C, Lassarre C, Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-1 and insulin.  Endocrinology. 1996;  137 3206-3212
• 67 Salahifar H, Firth S M, Baxter R C, Martin J L. Characterisation of an animo-terminal fragment of insulin-like growth factor binding protein-3 and its effects in MCF-7 breast cancer cells.  Growth Horm IGF Res. 2000;  10 367-377
• 68 Mohseni-Zadeh S, Binoux M. Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity if the receptor for its ligand, an alternative mechanism in the regulation of IGF action.  Endocrinology. 1997;  138 5645-5648
• 69 Maile L A. et al . The role of cell surface attachment and proteolysis in the insulin-like growth factor (IGF)-independent effects of IGF-binding protein-3 on apoptosis in breast epithelial cells.  Endocrinology. 1999;  140 (9) 4040-4045
• 70 Parker A. et al . Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-1.  Mol Biol Cell. 1998;  9 (9) 2383-2392
• 71 Andress D L. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor.  Am J Physiol. 1998;  274 (4 Pt 1) E744-E750
• 72 Oh Y. et al . Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells.  J Biol Chem. 1993;  268 (35) 26 045-26 048
• 73 Yamanaka Y. et al . Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule.  Endocrinology. 1999;  140 (3) 1319-1328
• 74 Leal S M, Liu Q, Huang S S, Huang J S. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor.  J Biol Chem. 1997;  272 (33) 20 572-20 576
• 75 Jones J I, Doerr M E, Clemmons D R. Cell migration: interactions among integrins, IGFs and IGFBPs.  Prog Growth Factor Res. 1995;  6 (2 - 4) 319-327
• 76 Irving J A, Lala P K. Functional role of cell surface integrins on human trophoblast cell migration: regulation by TGFβ, IGF-1I, and IGFBP-1.  Exp Cell Res. 1995;  217 (2) 419-427
• 77 Jones J I. et al . Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence.  Proc Natl Acad SciU S A. 1993;  90 (22) 10 553-10 557
• 78 Langkamp M, Elminger M W, Schuett B S, Ranke M B. Intracellular signalling of insulin-like growth factor binding protein-2.  Growth Hormone and IGF Research. 2000;  10 138, O31
• 79 Perks C M. et al . Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells.  J Mol Endocrinol. 1999;  22 (2) 141-150
• 80 Perks C. et al . IGFBP-3 modulates integrin signalling independently of IGF-1 in Hs578T human breast cancer cells.  Growth Hormone and IGF Research. 2000;  10 (4) A26, O6.4
• 81 Campbell P G, Durham S K, Hayes J D, Suwanichkul A, Powell D R. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin.  J Biol Chem. 1999;  274 (42) 30 215-30 221
• 82 Gui Y, Murphy L J. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): demonstration of IGF-1/IGFBP-3/fn ternary complexes in human plasma.  J Clin Endocrinol Metab,. 2001;  86 (5) 2104-2110
• 83 Shi Z. et al . ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3.  J Biol Chem. 2000;  275 (24) 18 574-18 580
• 84 Hwa V, Oh Y, Rosenfeld R G. The insulin-like growth factor-binding protein (IGFBP) superfamily.  Endocr Rev. 1999;  20 (6) 761-787
• 85 Lau L F, Lam S C. The CCN family of angiogenic regulators: the integrin connection.  Exp Cell Res. 1999;  248 (1) 44-57
• 86 McCaig C, Perks C, Holly J. MAP kinase inhibitor blocks IGF-1-independent effect of IGFBP-3 on breast epithelial cell survival and cell attachment.  Proceedings of the Endocrine Society’s 83rd Annual meeting. 2001;  2 268
• 87 McCaig C, Perks C M, Holly J M. Signalling pathways involved in the direct effects of IGFBP-5 on breast epithelial cell attachment and survival.  J Cell Biochem. 2002;  84 (4) 784-794
• 88 Hollowood A D. et al . Evidence implicating a mid-region sequence of IGFBP-3 in its specific IGF-1-independent actions.  J Cell Biochem. 2002;  86 (3) 583-589
• 89 Schedlich L J. et al . Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells.  J Biol Chem. 1998;  273 (29) 18 347-18 352
• 90 Liu B. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signalling and apoptosis.  J Biol Chem. 2000;  275 (43) 33 607-33 613
• 91 Fananyan S. et al . Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGFβ and the type II TGFβ receptor).  J Biol Chem. 2000;  275 (50) 39 146-39 151
• 92 Sommer A. et al . Properties of glycosylated and non-glycosylated human recombinant IGF binding protein-3 (IGFBP-3).  Growth Regul. 1993;  3 (1) 46-49
• 93 Shiry L, Blouin M J, Lenhest S. et al . Radiosensitizing effect of rhIGFBP-3 on MCF-7 breast cancer cells in vitro.  Horm Res. 2002;  58 266, Abstract 20-20
• 94 Yu Q, Banerjee K, Paterson J. Insulin-like growth factor binding protein-3: Single-agent and synergistic effects with chemotherapeutic drugs on solid tumour models.  Proceedings of the AACR, Washington D.C.. 2003;  44 172, Abstract 755
• 95 Francis M J, Peehl D M, Cohen P. Insulin-like growth factor binding protein (IGFBP-5 inhibits normal prostate epithelial cells but stimulates proliferation and telomerase activity in prostate cancer cells).  Proceedings of the AACR, Washington D.C.. 2003;  44 325, Abstract 1437
• 96 Yu H, Levesque M A, Khosravi M J, Papanastasiou-Diamandi A, Clark G, Diamandis E P. Insulin-like growth factor-binding protein-3 and breast cancer survival.  Int J Cancer. 1998;  79 (6) 624-628
• 97 Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis D L, Agnantis N J, Pavlidis N. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression.  Eur J Cancer. 2002;  38 (18) 2362-2370